Canagliflozin Safe


John B    28 June 2018

The drug was not associated with an increased risk for below-knee amputations in an observational study of more than 700,000 patients with type 2 diabetes in the OBSERVE-4D study (Canagliflozin vs Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation for Patients with T2DM — A Real-World Analysis of >700,000 US Patients) presented as a late-breaking poster on June 25 here at the American Diabetes Association (ADA) 2018 Scientific Sessions by John B. Buse, MD, PhD, director of the Diabetes Center at the University of North Carolina School of Medicine in Chapel Hill.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.